[Empagliflozin: current indications and aspects for daily clinical practice]

Abstract

Empagliflozin is one of the drugs belonging to the class of sodium-glucose cotransporter 2 inhibitors that inhibit the reabsorption of sodium and glucose, at the level of the proximal renal convoluted tubule. The "serendipity" of empagliflozin was based on its unexpected beneficial effects in diabetic patients and then in patients affected by heart failure and/or chronic kidney disease regardless of the presence of diabetes. The aim of this review is to offer a complete update on the body of evidence on empagliflozin in heart failure, and also to provide a useful tool in daily clinical practice.